Compare NRG Energy Inc (NRG) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NRG Energy Inc vs Novartis AG — how do they compare? NRG Energy Inc trades at $132.3 (market cap $27.55B), while Novartis AG trades at $153.88 (market cap $290.25B). The key difference: Novartis AG is far larger — about 10.5× NRG Energy Inc's market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| NRG | NVS | |
|---|---|---|
Market Cap | $27.55B | $290.25B |
Sector | Utilities | Health |
52-Week High | $184.03 | $168.62 |
52-Week Low | $120.65 | $113.50 |
Enterprise Value | $51.38B | $330.27B |
Dividend Yield | 1.46% | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NRG Energy trades at $131.60, up 1.93% over 24 hours, with a bearish technical signal despite bullish oscillators. Recent earnings show mixed results, beating estimates in Q3 and Q4 2025 but missing in Q1 2026. Revenue grew to $30.71 billion in 2025, though net income margin remains thin at 0.74%. Analyst consensus is strongly bullish with a $217.50 price target, supported by institutional buying interest.
The outlook is cautiously optimistic given strong analyst support and strategic positioning for power demand growth, but risks include volatile cash flows, high debt levels, and execution challenges. The stock offers potential upside if earnings momentum improves, yet investors face headwinds from margin pressure and macroeconomic sensitivity.
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
